Stevanato Group S.p.A.
NYSE:STVNMedical - Instruments & Supplies
+$0.67 today
- Market cap
- $4.20B
- Beta
- 0.78
- P/E (TTM)
- 29.9
- EPS (TTM)
- $0.52
- Dividend yield
- 0.35%
Volume 0.61M
Average 0.52M
STVN Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Stevanato Group S.p.A.NYSE: STVN
Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026
Net change in cash turns negative
Q2 FY2026 net change in cash was -€33.03M, compared with €3.45M a year earlier. Trailing-twelve-month net change in cash was -€15.17M.
Context
- Net change in cash amounted to 3.9% of revenue in FY2025, up 1.3 pp from a year earlier.
- Net change in cash increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly net change in cash holds near -€33.03M or moves back toward the trailing-twelve-month quarterly average of -€3.79M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
EUR · from the cash flow
- Latest · FY2025
- 43.94M EUR
- Year-over-year change
- +53.3%
- 4-year CAGR
- -37.9%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 43.94M | +53.3% |
| FY2024 | 2024-12-31 | 28.67M | +118.0% |
| FY2023 | 2023-12-31 | (159.14M) | +12.7% |
| FY2022 | 2022-12-31 | (182.3M) | -161.7% |
| FY2021 | 2021-12-31 | 295.44M | — |
Net Change in Cash vs competitors
How STVN compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -161.7% is the 8th highest of 11, against a peer median of +108.7%.
- Net change in cash amounts to 1.2% of revenue for STVN, versus a peer median of 2.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $576.54M USD | +447.4% | — | 3.8% | |
| LTM Jun 2026 | $209.68M USD | -876.6% | — | 8.1% | |
| LTM Jun 2026 | $142.5M USD | -191.9% | +14.1% | 2.2% | |
| LTM Jun 2026 | $106M USD | +453.3% | -26.4% | 2.0% | |
| LTM Sep 2026 | $56.35M USD | +143.1% | — | 3.5% | |
| LTM Mar 2026 | $38.9M USD | +74.3% | -12.5% | — | |
| LTM Jun 2026 | $28.07M USD | +147.4% | +107.9% | 0.7% | |
| LTM Jun 2026 | $20.09M USD | -144.3% | — | 0.8% | |
| LTM Jun 2026 | $16.83M USD | +233.2% | -59.5% | 2.2% | |
| LTM Jun 2026 | €15.17M EUR | -161.7% | — | 1.2% | |
| LTM Apr 2026 | $8.1M USD | -164.8% | — | 0.5% | |
| Peer median (excluding STVN) | — | +108.7% | -12.5% | 2.2% | |
Competitors are the stored peer set for STVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 165.67M | 187.64M | 189.55M | 160.29M | 134.32M |
| Depreciation & Amortization | 56.38M | 64.82M | 78.48M | 80.65M | 88.57M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | (41.63M) | (117.74M) | (102.48M) | (17.41M) | 48.63M |
| Accounts Receivables | (54.77M) | (46.42M) | (93.86M) | (3.83M) | 855.83K |
| Inventory | (31.2M) | (107.37M) | (113.59M) | 12.31M | (39.82M) |
| Accounts Payables | 44.34M | 36.05M | 104.97M | (25.89M) | 87.59M |
| Other Working Capital | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | (47.09M) | (31.41M) | (60.34M) | (67.76M) | 3.27M |
| Operating Cash Flow | 133.34M | 103.31M | 105.21M | 155.78M | 274.79M |
| Capital Expenditures | (113.18M) | (243.13M) | (441.93M) | (313.57M) | (253.35M) |
| Acquisitions (Net) | 14.81M | 0 | (3.59M) | (175K) | 1.79M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 773K | 31K | 0 | 0 | 241.09K |
| Other Investing Activities | (4.32M) | (7.95M) | 15.6M | (7.44M) | 0 |
| Investing Cash Flow | (96.43M) | (242.95M) | (421.22M) | (310.21M) | (262.15M) |
| Debt Repayment | (120.18M) | (31.04M) | 172.57M | 27.91M | 41.38M |
| Common Stock Issued | 380.09M | 0 | 0 | 169.77M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (11.2M) | (13.5M) | (14.29M) | (14.46M) | (14.16M) |
| Other Financing Activities | 6.13M | 0 | (250K) | 0 | (6.03M) |
| Financing Cash Flow | 254.85M | (44.54M) | 158.03M | 183.22M | 21.19M |
| Effect of Forex Changes | 3.68M | 1.88M | (1.16M) | (115K) | 10.11M |
| Net Change in Cash | 295.44M | (182.3M) | (159.14M) | 28.67M | 43.94M |
| Free Cash Flow | 20.16M | (139.82M) | (336.72M) | (157.8M) | 21.44M |
Stevanato Group S.p.A.
NYSE:STVN
Intrinsic Alpha fair value
Locked
Current Price
$15.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.